Jimmie Evans always knew he wanted to work in healthcare. And when he needed some dental work because of a sports injury, he was so impressed with the care he received that he thought dentistry was the right fit for him. That was the plan, at least, when he started as an undergraduate at the University of Arizona. But then he took a summer job working in a laboratory and quickly realized that the lab bench was where he really belonged. “I just loved it, the exploration and finding new things.”
CND Life Sciences is pleased to host an educational webinar discussing the science and utility of our Syn-One Test™, the first in-office, cutaneous diagnostic tool for Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder.
Having a core mission is foundational for any endeavor, and ours at CND Life Sciences is to advance the care of patients who face a potential diagnosis of a neurodegenerative disease. But just as important are our values–they are our guiding principles as we strive to further our mission.
Al-Qassabi and colleagues recently published a study in Movement Disorders that examined whether 3-mm skin punch biopsies could be used to detect synuclein pathology in patients with REM sleep behavior disorder (RBD).
CND Life Sciences continues to increase awareness and adoption of the skin-based Syn-One Test™ for Parkinson’s disease, dementia with Lewy bodies, and other synucleinopathies, now with the new “Power of Proof” campaign, which will appear across several top neurology journals and websites.
At the 2021 American Academy of Neurology meeting last month, Dr Alexandru Barboi and colleagues presented their observations on the use of the Syn-One Test™ in the evaluation of patients with autonomic symptoms.
A team of skilled laboratory professionals are the engine that keeps CND Life Sciences running every day. From the moment a Syn-One Test™ sample arrives, it must be handled and processed according to strict specifications.
In the next installment of our Patient Matters video series, Daryn Kagan talks with Alvin, a patient who was living with unexplained fatigue in his legs.
In a new effort to increase awareness and adoption of the skin-based Syn-One Test™ for Parkinson’s disease, dementia with Lewy bodies, and other synucleinopathies, CND has launched a targeted print and digital campaign across several top neurology journals and websites.